GT Biopharma Deploys AI to Advance Multiple Drug Candidates into Pre-IND by 2027
NKTX•GT Biopharma has implemented AI-driven sequence and structural analysis tools across its NK cell engager discovery and protein-engineering processes, aiming to reduce trial-and-error costs and timelines. The company expects multiple new development candidates to enter pre-IND studies in 2027 while advancing GTB-3650 and GTB-5550 through Phase 1, with the first GTB-5550 patient dosed in May 2026.
1. AI Integration in Discovery
GT Biopharma has incorporated AI-based sequence and structural analyses into its discovery and protein-engineering workflows. These tools prioritize molecules with optimal binding, stability and developability profiles before bench testing, markedly reducing reliance on costly trial-and-error experiments.
2. Pipeline Expansion and Pre-IND Goals
The company anticipates multiple new NK cell engager candidates will progress into pre-IND development in 2027. This expansion targets indications beyond oncology, leveraging AI to accelerate timelines and enhance the probability of clinical success.
3. Progress of Lead Clinical Programs
GTB-3650, targeting CD33-expressing hematologic malignancies, and GTB-5550, targeting B7-H3 solid tumors, remain in Phase 1 trials. The first GTB-5550 patient was dosed in May 2026, underscoring clinical execution alongside discovery efforts.
4. Strategic Benefits and Risk Outlook
AI-guided design aims to lower development costs, compress timelines and improve molecule manufacturability. Despite these advantages, the company faces typical micro-cap biotech risks, including clinical trial outcomes and regulatory hurdles.
